There has been a call for a summit between stakeholders and the Government to "address the ticking timebomb".
E
Read full storyExpress
Original source
Trending
How I’d redeem 100,000 Chase points for these long weekend tripsGoogle’s new Googlebook has clever AI tricks. I’d still pick a Windows laptopSecurity Council LIVE: Deaths, demolitions spike in Gaza, West BankFront Porch: If you’re from Florida, you have a gator story - Thu, 15 Oct 2026 PSTBRC celebrates raising days of 3 units in DanapurNushrratt Bharuccha undergoes successful spine surgery after Bali accident, discharged from hospitalDivided Democrats should be careful what they wish for in the midtermsHorror Christmas deliveries warning as Royal Mail 'on brink of collapse'How I’d redeem 100,000 Chase points for these long weekend tripsGoogle’s new Googlebook has clever AI tricks. I’d still pick a Windows laptopSecurity Council LIVE: Deaths, demolitions spike in Gaza, West BankFront Porch: If you’re from Florida, you have a gator story - Thu, 15 Oct 2026 PSTBRC celebrates raising days of 3 units in DanapurNushrratt Bharuccha undergoes successful spine surgery after Bali accident, discharged from hospitalDivided Democrats should be careful what they wish for in the midtermsHorror Christmas deliveries warning as Royal Mail 'on brink of collapse'
Related Stories
Business1h ago
Eupraxia Pharmaceuticals Reaches its Enrollment Target for the RESOLVE Trial Investigating EP-104GI for the Treatment of Eosinophilic Esophagitis
VANCOUVER, British Columbia, Oct. 15, 2026 (GLOBE NEWSWIRE) -- Eupraxia Pharmaceuticals Inc. ("Eupraxia" or the "Company") (NASDAQ:EPRX) (TSX:EPRX), a clinical-stage biotechnology company leveraging its proprietary Diffusphere™ technology designed to optimize local, controlled drug delivery for applications with significant unmet need, today announced that the ongoing RESOLVE study evaluating the safety and efficacy of EP-104GI for the treatment of Eosinophilic Esophagitis (“EoE”) has reached its enrollment target.
GGlobe Newswire
Business1h ago
Apterra Infrastructure Capital Names Josh Mintz Chief Financial Officer
NEW YORK, Oct. 15, 2026 (GLOBE NEWSWIRE) -- Apterra Infrastructure Capital (“Apterra” or the “Company”), a leading infrastructure finance platform and affiliate of Apollo (NYSE: APO), today announced that Josh Mintz has joined Apterra as Chief Financial Officer. Mintz brings more than 15 years of experience across private credit, alternative asset management and financial services, and will report to Co-CEOs Michael Pantelogianis and Ralph Cho.
GGlobe Newswire
Brief
Business7h ago
South Korea's KOSPI closes at 6-month low as chipmakers slump on AI worries
Seoul and Tokyo bore the brunt of the selling as traders bailed out of once-imperious chipmakers.
CChannel Newsasia
Brief
Business7h ago
Asian markets sell off after US inflation fuels rate hike bets
Seoul and Tokyo bore the brunt of the selling as traders bailed out of once-imperious chipmakers.
CChannel Newsasia